Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.19 ▼ -0.04
(-0.95%)
MKT CAP: $206.8M • VOL: 1.97M
52W L $3 52W H $15
ARTV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $251.0K | $32.9M |
| YoY Revenue Growth % | — | -99.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$89.8M | -$67.3M | -$30.7M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$83.9M | -$65.4M | -$28.7M |
| EBITDA (Normalized) | -$87.7M | -$66.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$76.8M | -$55.0M | -$47.4M |
| Capital Expenditures (CapEx) | $2.6M | $642.0K | — |
| Free Cash Flow (FCF) | -$79.3M | -$55.7M | -$47.4M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -36.3% | — |
| Cash & Short-Term Equivalents | $26.7M | $40.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $110.0M | $186.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARTV.